Trial Profile
A multi-centre, randomized, placebo-controlled, double-blind trial to assess the efficacy and safety of nitroglycerin sublingual powder on walking distance in a scheduled forced titration design in patients with peripheral arterial occlusive disease (PAOD) and intermittent claudication.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Apr 2021
Price :
$35
*
At a glance
- Drugs Nitroglycerin (Primary)
- Indications Intermittent claudication; Peripheral arterial occlusive disorders
- Focus Proof of concept; Therapeutic Use
- Sponsors Pohl-Boskamp
- 01 Mar 2021 Primary endpoint (One primary endpoint is defined as the increase in “walking distance” measured as initial claudication distance (ICD) at Visit 7 (end of treatment period) compared to baseline. A further primary endpoint is the walking distance by absolute claudication distance (ACD) at Visit 7 (end of treatment period) compared to baseline), has not been met according to Results published in the European Journal of Vascular and En
- 01 Mar 2021 Results published in the European Journal of Vascular and Endovascular Surgery
- 04 Jan 2019 Status changed from recruiting to completed.